Salute e Benessere
Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025
Overview of treatment advances with complement Inhibitors in patients with Paroxysmal Nocturnal Haemoglobinuria.
Optimising PNH treatment with the complement inhibitor Pegcetacoplan: A case report.
User experience with Pegcetacoplan on-body Injector in patients with Paroxysmal Nocturnal Hemoglobinuria.
7 December 2025
12:00 PM - 1:30 PM ET
1:00 PM - 1:15 PM ET
OCCC – W304EFGH
539
6 December 2025
5:30 PM - 7:30 PM ET
OCCC - West Halls B3-B4
2679
6 December 2025
5:30 PM - 7:30 PM ET
OCCC - West Halls B3-B4
1286
6 December 2025
5:30 PM - 7:30 PM ET
OCCC - West Halls B3-B4
1290
8 December 2025
6:00 PM - 8:00 PM ET
OCCC - West Halls B3-B4
4846
6 December 2025
5:30 PM - 7:30 PM ET
OCCC - West Halls B3-B4
7 December 2025
6:00:00 PM – 6:00:00 PM ET
OCCC - West Halls B3-B4
8 December 2025
6:00 PM - 8:00 PM ET
OCCC - West Halls B3-B4
6 December 2025
5:30 PM - 7:30 PM ET
OCCC - West Halls B3-B4
6 December 2025
5:30 PM – 7:30 PM ET
OCCC – West Halls B3-B4
8 December 2025
6:00 PM - 8:00 PM ET
OCCC - West Halls B3-B4
7 December 2025
6:00 PM - 8:00 PM ET
OCCC - West Halls B3-B4
8 December 2025
6:00 PM - 8:00 PM ET
OCCC - West Halls B3-B4
Malignancies: Real-World Experiences
7 December 2025
4:30 PM - 6:00 PM ET
5:30 PM - 5:45 PM
OCCC - W414CD
6 December 2025
5:30 PM - 7:30 PM ET
OCCC - West Halls B3-B4
7 December 2025
6:00 PM - 8:00 PM ET
OCCC - West Halls B3-B4
7 December 2025
6:00 PM - 8:00 PM ET
OCCC - West Halls B3-B4
6:00 PM - 8:00 PM ET
OCCC - West Halls B3-B4
ALTUVOCT (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (HA). ALTUVOCT can be used for all age groups and any disease severity.
Sobi and Sanofi collaborate on the development and commercialisation of ALTUVOCT® (efanesoctocog alfa), or ALTUVIIIO™ in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially
Europe , North Africa ,
Russia , and most Middle Eastern markets). Sanofi has final development and commercialisation rights in
North America and all other regions in the world excluding the Sobi territory.
Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 and C3b inhibitor designed to regulate excessive activation of the complement cascade, part of the body's immune system, which can lead to the onset and progression of many serious diseases. Aspaveli/Empaveli is approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) in the US, European Union, and other countries globally, and for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in
the United States . It is under regulatory review for C3G and primary IC-MPGN in the European Union and other countries globally.
Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialisation rights for systemic pegcetacoplan, and its opt-in rights for future development programs are unchanged, exercisable at any time prior to commercialisation. Apellis has exclusive U.S. commercialisation rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy.
Doptelet (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) scheduled to undergo an invasive procedure. Doptelet is also approved for the treatment of chronic ITP in pediatric patients.
Gamifant is an anti-IFNγ antibody that binds free and receptor-bound IFNγ, which when secreted in an uncontrolled manner can cause hyperinflammation. Gamifant is indicated for intravenous infusion over one hour and is FDA approved for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) in Still's disease.
Vonjo (pacritinib) is a kinase inhibitor indicated in
the United States for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. Vonjo is also being investigated for other rare hematologic conditions, including VEXAS syndrome.
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe , North America , the Middle East , Asia and Australia . In 2024, revenue amounted to SEK 26 billion . Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-to-showcase-scientific-advances-and-commitment-to-haematology-at-ash-2025,c4277861
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/sobi-to-showcase-scientific-advances-and-commitment-to-haematology-at-ash-2025-302634280.html